Adenozinski A1 receptor (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Adenozinski A1 receptor" in Serbian language version.

refsWebsite

Global rank Serbian rank

8nih.gov

4^th place

8^th place

7doi.org

2^nd place

4^th place

1ahajournals.org

3,608^th place

3,815^th place

ahajournals.org

circ.ahajournals.org

Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT (2002). „BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy”. Circulation. 105 (11): 1348—53. PMID 11901047. doi:10.1161/hc1102.105264.

doi.org

Townsend-Nicholson A, Baker E, Schofield PR, Sutherland GR (1995). „Localization of the adenosine A₁ receptor subtype gene (ADORA1) to chromosome 1q32.1”. Genomics. 26 (2): 423—5. PMID 7601478. doi:10.1016/0888-7543(95)80236-F.
Elmenhorst D, Meyer PT, Winz OH, Matusch A, Ermert J, Coenen HH, Basheer R, Haas HL, Zilles K, Bauer A (2007). „Sleep deprivation increases A₁ adenosine receptor binding in the human brain: a positron emission tomography study”. J. Neurosci. 27 (9): 2410—5. PMID 17329439. doi:10.1523/JNEUROSCI.5066-06.2007.
Tawfik HE, Schnermann J, Oldenburg PJ, Mustafa SJ (2005). „Role of A₁ adenosine receptors in regulation of vascular tone”. Am. J. Physiol. Heart Circ. Physiol. 288 (3): H1411—6. PMID 15539423. doi:10.1152/ajpheart.00684.2004.
Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT (2002). „BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy”. Circulation. 105 (11): 1348—53. PMID 11901047. doi:10.1161/hc1102.105264.
Greenberg B, Thomas I, Banish D, Goldman S, Havranek E, Massie BM, Zhu Y, Ticho B, Abraham WT (2007). „Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study”. Journal of the American College of Cardiology. 50 (7): 600—6. PMID 17692744. doi:10.1016/j.jacc.2007.03.059.
Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC (2007). „The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance”. Journal of the American College of Cardiology. 50 (16): 1551—60. PMID 17936154. doi:10.1016/j.jacc.2007.07.019.
Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM (2008). „The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment”. Journal of Cardiac Failure. 14 (8): 631—40. PMID 18926433. doi:10.1016/j.cardfail.2008.08.010.

nih.gov

ncbi.nlm.nih.gov

Townsend-Nicholson A, Baker E, Schofield PR, Sutherland GR (1995). „Localization of the adenosine A₁ receptor subtype gene (ADORA1) to chromosome 1q32.1”. Genomics. 26 (2): 423—5. PMID 7601478. doi:10.1016/0888-7543(95)80236-F.
Elmenhorst D, Meyer PT, Winz OH, Matusch A, Ermert J, Coenen HH, Basheer R, Haas HL, Zilles K, Bauer A (2007). „Sleep deprivation increases A₁ adenosine receptor binding in the human brain: a positron emission tomography study”. J. Neurosci. 27 (9): 2410—5. PMID 17329439. doi:10.1523/JNEUROSCI.5066-06.2007.
Tawfik HE, Schnermann J, Oldenburg PJ, Mustafa SJ (2005). „Role of A₁ adenosine receptors in regulation of vascular tone”. Am. J. Physiol. Heart Circ. Physiol. 288 (3): H1411—6. PMID 15539423. doi:10.1152/ajpheart.00684.2004.
Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001). „International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors”. Pharmacol. Rev. 53 (4): 527—52. PMID 11734617.
Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT (2002). „BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy”. Circulation. 105 (11): 1348—53. PMID 11901047. doi:10.1161/hc1102.105264.
Greenberg B, Thomas I, Banish D, Goldman S, Havranek E, Massie BM, Zhu Y, Ticho B, Abraham WT (2007). „Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study”. Journal of the American College of Cardiology. 50 (7): 600—6. PMID 17692744. doi:10.1016/j.jacc.2007.03.059.
Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC (2007). „The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance”. Journal of the American College of Cardiology. 50 (16): 1551—60. PMID 17936154. doi:10.1016/j.jacc.2007.07.019.
Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM (2008). „The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment”. Journal of Cardiac Failure. 14 (8): 631—40. PMID 18926433. doi:10.1016/j.cardfail.2008.08.010.